Xanax is not approved to treat depression on its own, and most psychiatrists would not prescribe it as a standalone antidepressant. The FDA approves Xanax (alprazolam) for two conditions: generalized anxiety disorder and panic disorder. Its label does note that “anxiety associated with depression is responsive to XANAX,” but that’s a narrow statement about the anxiety piece of a depressive episode, not about depression itself.
So why does the question keep coming up? Because Xanax can make you feel better fast, and some older research suggests it has genuine antidepressant properties. The reality is more complicated, and the risks for someone with depression are serious enough that the quick relief isn’t worth it for most people.
What the Research Actually Shows
A meta-analysis reviewing multiple clinical trials found that alprazolam’s antidepressant effect was comparable to that of low-dose tricyclic antidepressants (an older class of antidepressant). That sounds promising until you read the fine print. The reviewers at the University of York’s Centre for Reviews and Dissemination cautioned that the studies had significant gaps: very few included patients with severe depression, the comparison antidepressants were used at lower-than-typical doses, and almost none looked at long-term outcomes. Their conclusion was that it’s not possible to confidently identify which patients, if any, would benefit from alprazolam the way they would from a true antidepressant.
The mechanism is different, too. Standard antidepressants like SSRIs work by increasing serotonin availability in the brain, a process that takes weeks to produce noticeable mood improvement. Xanax enhances the activity of GABA, a chemical that calms neural activity. This produces rapid relief from anxiety and tension, often within 30 to 60 minutes. That immediate calm can feel like your depression is lifting, but what’s actually happening is closer to sedation and anxiety reduction than a correction of the underlying mood problem.
Why Quick Relief Can Backfire
The speed of Xanax is both its appeal and its trap. Because you feel a clear, almost instant shift after taking it, your brain forms a strong association between the pill and relief. SSRIs don’t create that link because their benefits build gradually over four to six weeks. That slow onset is frustrating, but it also means SSRIs carry almost no risk of psychological dependence. With Xanax, physical dependence can develop in as little as a few weeks of regular use.
Stopping Xanax after your body has adjusted to it triggers withdrawal symptoms that can include rebound anxiety, insomnia, and notably, worsening depression. After about a week of withdrawal, the physical symptoms tend to ease, but cravings, depression, insomnia, and even suicidal thoughts can emerge or intensify during this later phase. For someone who started taking Xanax because they were already depressed, this creates a painful cycle: the drug masks symptoms temporarily, then makes them worse when it’s discontinued.
A Concerning Link to Suicidal Behavior
Perhaps the most important data for anyone with depression to understand involves suicide risk. A large study published in Psychiatry Research found that alprazolam was associated with more than double the risk of suicide attempts compared to periods when the same individuals were not taking the drug. The risk also increased with duration of use: at the most common dose (0.5 mg), each additional month of treatment was linked to a 5% increase in suicidal events. In a separate analysis of 52 medications used alongside other treatments, alprazolam was one of only two drugs associated with higher suicide risk.
This doesn’t necessarily mean Xanax directly causes suicidal behavior. People prescribed Xanax may already be in more acute distress. But the pattern is consistent enough that prescribing it to someone whose primary problem is depression, rather than anxiety, raises real safety concerns.
When Doctors Do Prescribe It Alongside Antidepressants
There is one scenario where Xanax sometimes plays a limited role in treating depression. When someone starts an SSRI or similar antidepressant, the first few weeks can actually increase anxiety before the therapeutic effect kicks in. Some clinicians prescribe a short course of a benzodiazepine during this window to help patients tolerate the transition. The idea is to use Xanax as a temporary bridge, not a long-term solution, then taper off once the antidepressant reaches full effect.
Even this practice is debated. Some experts question whether adding a drug with dependence potential during such a vulnerable period is worth the trade-off, especially when dose adjustments to the antidepressant can often manage the early-phase anxiety instead. When benzodiazepines are used this way, it’s typically for days to a few weeks at most, with a clear plan for discontinuation built in from the start.
Better Options for Depression
SSRIs and a newer class called SNRIs remain the standard first-line treatments for depression. They take longer to work, but they address the neurochemical imbalances more directly, carry no dependence risk, and have decades of evidence supporting their use in both moderate and severe depression. If the first medication doesn’t work well enough, switching to another antidepressant or adding a second medication from a different class is the typical next step.
For depression that includes significant anxiety, which is extremely common, the overlap in symptoms is part of what makes Xanax feel effective. But SSRIs treat both anxiety and depression over time, without the withdrawal problems or escalating suicide risk seen with benzodiazepines. Cognitive behavioral therapy is another well-supported option, either alone for mild to moderate depression or combined with medication for more severe cases.
If you’re currently taking Xanax and feel it’s helping your mood, that experience is real, but it likely reflects anxiety relief and sedation rather than a true antidepressant effect. Transitioning to a medication designed to treat depression will generally produce more stable, lasting improvement without the risks that come with long-term benzodiazepine use.